{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:47:29Z","timestamp":1789469249537,"version":"build-2803163510"},"reference-count":296,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000723","name":"Tenovus","doi-asserted-by":"publisher","award":["PhD2015\/L13"],"award-info":[{"award-number":["PhD2015\/L13"]}],"id":[{"id":"10.13039\/501100000723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of genetically modified replicating viruses as anti-cancer agents. Whilst T-Vec is promising as a locally delivered virotherapy, especially in combination with immune-checkpoint inhibitors, the quest continues for a virus capable of specific tumour cell killing via systemic administration. One candidate is oncolytic adenovirus (Ad); it\u2019s double stranded DNA genome is easily manipulated and a wide range of strategies and technologies have been employed to empower the vector with improved pharmacokinetics and tumour targeting ability. As well characterised clinical and experimental agents, we have detailed knowledge of adenoviruses\u2019 mechanisms of pathogenicity, supported by detailed virological studies and in vivo interactions. In this review we highlight the strides made in the engineering of bespoke adenoviral vectors to specifically infect, replicate within, and destroy tumour cells. We discuss how mutations in genes regulating adenoviral replication after cell entry can be used to restrict replication to the tumour, and summarise how detailed knowledge of viral capsid interactions enable rational modification to eliminate native tropisms, and simultaneously promote active uptake by cancerous tissues. We argue that these designer-viruses, exploiting the viruses natural mechanisms and regulated at every level of replication, represent the ideal platforms for local overexpression of therapeutic transgenes such as immunomodulatory agents. Where T-Vec has paved the way, Ad-based vectors now follow. The era of designer oncolytic virotherapies looks decidedly as though it will soon become a reality.<\/jats:p>","DOI":"10.3390\/cancers10060201","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T11:06:06Z","timestamp":1528974366000},"page":"201","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Designer Oncolytic Adenovirus: Coming of Age"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-0531","authenticated-orcid":false,"given":"Alexander","family":"Baker","sequence":"first","affiliation":[{"name":"Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Aguirre-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnel","family":"Halld\u00e9n","sequence":"additional","affiliation":[{"name":"Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-1761","authenticated-orcid":false,"given":"Alan","family":"Parker","sequence":"additional","affiliation":[{"name":"Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"ref_1","unstructured":"Medawar, P.B., and Medawar, J.S. (1985). Aristotle to Zoos: A Philosophical Dictionary of Biology, Harvard University Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1073\/pnas.39.11.1147","article-title":"Ascites Tumor-Virus System as a Biological Tool","volume":"39","author":"Koprowski","year":"1953","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cytogfr.2010.02.006","article-title":"Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics","volume":"21","author":"Harrington","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sanchala, D.S., Bhatt, L.K., and Prabhavalkar, K.S. (2017). Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00270"},{"key":"ref_5","unstructured":"(2018, March 18). Search of: Adenovirus OR Adv OR Adenoviral OR Ad|Recruiting, Not yet Recruiting, Active, Not Recruiting, Enrolling by Invitation Studies|Cancer NOT Communicable\u2014List Results\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=Cancer+NOT+communicable&term=adenovirus+OR+adv+OR+adenoviral+OR+ad&type=&rslt=&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&lupd_s=&lupd_e=."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.003087-0","article-title":"Adenoviruses: Update on structure and function","volume":"90","author":"Russell","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_7","unstructured":"(2018, March 18). Fields Virology\u2014NLM Catalog\u2014NCBI, Available online: https:\/\/www.ncbi.nlm.nih.gov\/nlmcatalog\/101601028."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/srep01812","article-title":"Molecular evolution of human adenoviruses","volume":"3","author":"Robinson","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_9","unstructured":"(2018, June 14). HAdV Working Group. Available online: http:\/\/hadvwg.gmu.edu\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/JVI.00354-11","article-title":"Using the Whole-Genome Sequence to Characterize and Name Human Adenoviruses","volume":"85","author":"Seto","year":"2011","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Twumasi-Boateng, K., Pettigrew, J.L., Kwok, Y.Y.E., Bell, J.C., and Nelson, B.H. (2018). Oncolytic viruses as engineering platforms for combination immunotherapy. Nat. Rev. Cancer, 1.","DOI":"10.1038\/s41568-018-0009-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_13","first-page":"133","article-title":"PEGylated adenovirus for targeted gene therapy","volume":"434","author":"Song","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/10430349950018021","article-title":"PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo","volume":"10","author":"Lachapelle","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/v2020468","article-title":"PEGylated Adenoviruses: From Mice to Monkeys","volume":"2","author":"Wonganan","year":"2010","journal-title":"Viruses"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1021\/nn8000565","article-title":"Nanoengineering artificial lipid envelopes around adenovirus by self-assembly","volume":"2","author":"Singh","year":"2008","journal-title":"ACS Nano"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1128\/JVI.00118-11","article-title":"Unnatural Amino Acid Incorporation onto Adenoviral (Ad) Coat Proteins Facilitates Chemoselective Modification and Retargeting of Ad Type 5 Vectors","volume":"85","author":"Banerjee","year":"2011","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s11095-011-0629-9","article-title":"Magnetic Nanoparticles Enhance Adenovirus Transduction In Vitro and In Vivo","volume":"29","author":"Sapet","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/viro.2002.1510","article-title":"Adenovirus\u2013Microbead Conjugates Possess Enhanced Infectivity: A New Strategy for Localized Gene Delivery","volume":"299","author":"Pandori","year":"2002","journal-title":"Virology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/nl0500555","article-title":"Covalently Linked Au Nanoparticles to a Viral Vector:\u2009 Potential for Combined Photothermal and Gene Cancer Therapy","volume":"6","author":"Everts","year":"2006","journal-title":"Nano Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1089\/hum.1998.9.12-1769","article-title":"\u03b2-Galactosidase Gene Transfer to Human Malignant Glioma In Vivo Using Replication-Deficient Retroviruses and Adenoviruses","volume":"9","author":"Puumalainen","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1099\/vir.0.82079-0","article-title":"Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: Manufacture on PER.C6 cells, tropism and immunogenicity","volume":"87","author":"Lemckert","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","article-title":"Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function","volume":"45","author":"Stanton","year":"2008","journal-title":"BioTechniques"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., and Fisher, K. (2008). Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002409"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2014.05.003","article-title":"Association of oncolytic adenoviruses with chemotherapies: An overview and future directions","volume":"90","author":"Bressy","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.mt.6300223","article-title":"Androgen Receptor Attenuation of Ad5 Replication: Implications for the Development of Conditionally Replication Competent Adenoviruses","volume":"15","author":"Li","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/80466","article-title":"Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)","volume":"6","author":"Ries","year":"2000","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_32","first-page":"1307","article-title":"Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer","volume":"22","author":"Xu","year":"2003","journal-title":"Ai Zheng Aizheng Chin. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","article-title":"Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial","volume":"10","author":"Lu","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"ref_34","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.cdd.4401941","article-title":"Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis","volume":"13","author":"White","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1128\/JVI.72.12.9479-9490.1998","article-title":"p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection","volume":"72","author":"Goodrum","year":"1998","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"Johnson","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the World First Oncolytic Virus Medicine and its Update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1038\/sj.onc.1209040","article-title":"Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus","volume":"24","author":"Berk","year":"2005","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1242\/jcs.01227","article-title":"Molecular mechanisms of E2F-dependent activation and pRB-mediated repression","volume":"117","author":"Frolov","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kuryk, L., Vassilev, L., Ranki, T., Hemminki, A., Karioja-Kallio, A., Levalampi, O., Vuolanto, A., Cerullo, V., and Pesonen, S. (2017). Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102\u2014Support for clinical studies on advanced cancer treatment. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182715"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/gt.2009.103","article-title":"A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses","volume":"16","author":"Rojas","year":"2009","journal-title":"Gene Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1078-0432.CCR-14-2213","article-title":"Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression","volume":"21","author":"Rojas","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2013.229","article-title":"ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models","volume":"25","author":"Dong","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-09-1960","article-title":"Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant (Ad\u0394\u0394) in prostate and pancreatic cancers","volume":"16","author":"Yanover","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/gt.2011.141","article-title":"The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models","volume":"18","author":"Cherubini","year":"2011","journal-title":"Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41389-017-0020-8","article-title":"Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad through Bcl-2-dependent attenuation of autophagy","volume":"7","author":"Millan","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"15703","DOI":"10.18632\/oncotarget.7310","article-title":"The E1B19K-deleted oncolytic adenovirus mutant AdDelta19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11","volume":"7","author":"Pantelidou","year":"2016","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/1535-7163.MCT-17-0671","article-title":"The Novel Oncolytic Adenoviral Mutant Ad5-3\u0394-A20T Retargeted to \u03b1v\u03b26 Integrins Efficiently Eliminates Pancreatic Cancer Cells","volume":"17","author":"Man","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1172\/JCI200523183","article-title":"Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma","volume":"115","author":"Bates","year":"2005","journal-title":"J. Clin Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1078-0432.CCR-13-1504","article-title":"Altered microenvironment promotes progression of preinvasive breast cancer: Myoepithelial expression of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts recurrence","volume":"20","author":"Allen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"Carlisle","year":"2009","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1089\/hum.2011.218","article-title":"Combined Fiber Modifications Both to Target \u03b1v\u03b26 and Detarget the Coxsackievirus\u2013Adenovirus Receptor Improve Virus Toxicity Profiles In Vivo but Fail to Improve Antitumoral Efficacy Relative to Adenovirus Serotype 5","volume":"23","author":"Coughlan","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/gt.2014.2","article-title":"Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood","volume":"21","author":"Di","year":"2014","journal-title":"Gene Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","article-title":"Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators","volume":"4","author":"Dyer","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Salazar","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.omto.2016.12.001","article-title":"OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution","volume":"4","author":"Kuhn","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_63","first-page":"2559","article-title":"Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.gt.3301987","article-title":"Telomerase-dependent oncolytic adenovirus for cancer treatment","volume":"10","author":"Huang","year":"2003","journal-title":"Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","article-title":"A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer","volume":"14","author":"Small","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_66","unstructured":"Goldufsky, J., Sivendran, S., Harcharik, S., Pan, M., Bernardo, S., Stern, R.H., Friedlander, P., Ruby, C.E., Saenger, Y., and Kaufman, H.L. (2018, May 16). Oncolytic Virus Therapy for Cancer. Available online: https:\/\/www.dovepress.com\/oncolytic-virus-therapy-for-cancer-peer-reviewed-article-OV."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_69","first-page":"1009","article-title":"ONYX-015 Works Synergistically with Chemotherapy in Lung Cancer Cell Lines and Primary Cultures Freshly Made from Lung Cancer Patients","volume":"60","author":"You","year":"2000","journal-title":"Cancer Res."},{"key":"ref_70","first-page":"517","article-title":"Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel","volume":"61","author":"Yu","year":"2001","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1158\/1535-7163.MCT-08-0901","article-title":"Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_72","first-page":"4074","article-title":"G2 Arrest in Response to Topoisomerase II Inhibitors: The Role of p53","volume":"63","author":"Clifford","year":"2003","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/1078-0432.CCR-05-1892","article-title":"Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan","volume":"12","author":"Alonso","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/cgt.2010.37","article-title":"Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma","volume":"17","author":"Ma","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1089\/hum.2010.019","article-title":"Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts","volume":"21","author":"Radhakrishnan","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1038\/sj.onc.1204861","article-title":"Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus","volume":"20","author":"White","year":"2001","journal-title":"Oncogene"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Miranda, E., Maya Pineda, H., Oberg, D., Cherubini, G., Garate, Z., Lemoine, N.R., and Hallden, G. (2012). Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046617"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/hum.2012.046","article-title":"Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdDeltaDelta and Dietary Phytochemicals in Prostate Cancer Models","volume":"23","author":"Adam","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","article-title":"Recent advances in oncolytic adenovirus therapies for cancer","volume":"21","author":"Suzuki","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00109-016-1453-9","article-title":"Oncolytic viruses-immunotherapeutics on the rise","volume":"94","author":"Keller","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors\u2014An evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.coviro.2015.03.009","article-title":"Oncolytic adenovirus research evolution: From cell-cycle checkpoints to immune checkpoints","volume":"13","author":"Jiang","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Huang, J.L., LaRocca, C.J., and Yamamoto, M. (2016). Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts. Biomedicines, 4.","DOI":"10.3390\/biomedicines4030023"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Martin, N.T., and Bell, J.C. (2018). Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Mol. Ther., 26.","DOI":"10.1016\/j.ymthe.2018.04.001"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic Viruses: Therapeutics with an Identity Crisis","volume":"9","author":"Breitbach","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2217\/imt.13.123","article-title":"Evolution of oncolytic viruses: Novel strategies for cancer treatment","volume":"5","author":"Atherton","year":"2013","journal-title":"Immunotherapy"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/cgt.2011.45","article-title":"An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine","volume":"18","author":"Bhattacharyya","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bramante, S., Kaufmann, J.K., Veckman, V., Liikanen, I., Nettelbeck, D.M., Hemminki, O., Vassilev, L., Cerullo, V., Oksanen, M., and Heiskanen, R. (2015). Treatment of melanoma with a serotype 5\/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. Int. J. Cancer.","DOI":"10.1002\/ijc.29536"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","article-title":"Talimogene Laherparepvec: First Global Approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"ref_92","first-page":"691","article-title":"Growth-inhibitory Effects of CD40 Ligand (CD154) and Its Endogenous Expression in Human Breast Cancer","volume":"7","author":"Tong","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_93","first-page":"7556","article-title":"Recombinant CD40 Ligand Therapy Has Significant Antitumor Effects on CD40-positive Ovarian Tumor Xenografts Grown in SCID Mice and Demonstrates an Augmented Effect with Cisplatin","volume":"61","author":"Ghamande","year":"2001","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1007\/s13277-014-2407-x","article-title":"Multifunctional CD40L: Pro- and anti-neoplastic activity","volume":"35","author":"Korniluk","year":"2014","journal-title":"Tumor Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-08-1360","article-title":"Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells","volume":"15","author":"Gomes","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","article-title":"Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus","volume":"72","author":"Diaconu","year":"2012","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/gt.2016.80","article-title":"Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment","volume":"24","author":"Eriksson","year":"2017","journal-title":"Gene Ther."},{"key":"ref_100","first-page":"2541","article-title":"Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12\u2013Associated Toxicity and Interferon-\u03b3 Production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/gt.2013.40","article-title":"Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer","volume":"20","author":"Freytag","year":"2013","journal-title":"Gene Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","article-title":"Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer","volume":"89","author":"Freytag","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1556\/EuJMI.4.2014.1.2","article-title":"Human adenovirus: Viral pathogen with increasing importance","volume":"4","author":"Ghebremedhin","year":"2014","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1128\/JVI.01964-09","article-title":"Structure of Adenovirus Type 21 Knob in Complex with CD46 Reveals Key Differences in Receptor Contacts among Species B Adenoviruses","volume":"84","author":"Cupelli","year":"2010","journal-title":"J. Virol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JVI.75.6.2972-2981.2001","article-title":"Adenovirus Type 5 Viral Particles Pseudotyped with Mutagenized Fiber Proteins Show Diminished Infectivity of Coxsackie B-Adenovirus Receptor-Bearing Cells","volume":"75","author":"Jakubczak","year":"2001","journal-title":"J. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1126\/science.286.5444.1568","article-title":"Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae","volume":"286","author":"Roelvink","year":"1999","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"12785","DOI":"10.1128\/JVI.01732-07","article-title":"Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob","volume":"81","author":"Wang","year":"2007","journal-title":"J. Virol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11346","DOI":"10.1128\/JVI.01825-13","article-title":"Structural and Functional Studies on the Interaction of Adenovirus Fiber Knobs and Desmoglein 2","volume":"87","author":"Wang","year":"2013","journal-title":"J. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.2267","article-title":"The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis","volume":"17","author":"Nilsson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","article-title":"Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer","volume":"114","author":"Alba","year":"2009","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"12249","DOI":"10.1128\/JVI.01584-07","article-title":"Fiber Shaft-Chimeric Adenovirus Vectors Lacking the KKTK Motif Efficiently Infect Liver Cells In Vivo","volume":"81","author":"Paolo","year":"2007","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.mt.6300094","article-title":"Adenovirus 5 Fibers Mutated at the Putative HSPG-binding Site Show Restricted Retargeting with Targeting Peptides in the HI Loop","volume":"15","author":"Kritz","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1128\/jvi.67.9.5198-5205.1993","article-title":"Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells","volume":"67","author":"Bai","year":"1993","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.gt.3302408","article-title":"Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains","volume":"12","author":"Henning","year":"2005","journal-title":"Gene Ther."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Stichling, N., Suomalainen, M., Flatt, J.W., Schmid, M., Pacesa, M., Hemmi, S., Jungraithmayr, W., Maler, M.D., Freudenberg, M.A., and Pl\u00fcckthun, A. (2018). Lung macrophage scavenger receptor SR-A6 (MARCO) is an adenovirus type-specific virus entry receptor. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006914"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"15191","DOI":"10.1073\/pnas.261452898","article-title":"The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction","volume":"98","author":"Cohen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1128\/JVI.78.12.6431-6438.2004","article-title":"Biodistribution of Radioiodinated Adenovirus Fiber Protein Knob Domain after Intravenous Injection in Mice","volume":"78","author":"Awasthi","year":"2004","journal-title":"J. Virol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1128\/JVI.72.10.7909-7915.1998","article-title":"The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F","volume":"72","author":"Roelvink","year":"1998","journal-title":"J. Virol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1126\/science.286.5444.1579","article-title":"Structural Analysis of the Mechanism of Adenovirus Binding to Its Human Cellular Receptor, CAR","volume":"286","author":"Bewley","year":"1999","journal-title":"Science"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"33704","DOI":"10.1074\/jbc.M605316200","article-title":"Structural and Mutational Analysis of Human Ad37 and Canine Adenovirus 2 Fiber Heads in Complex with the D1 Domain of Coxsackie and Adenovirus Receptor","volume":"281","author":"Seiradake","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/JVI.74.6.2804-2813.2000","article-title":"Identification of Contact Residues and Definition of the CAR-Binding Site of Adenovirus Type 5 Fiber Protein","volume":"74","author":"Kirby","year":"2000","journal-title":"J. Virol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1128\/JVI.73.11.9508-9514.1999","article-title":"Mutations in the DG Loop of Adenovirus Type 5 Fiber Knob Protein Abolish High-Affinity Binding to Its Cellular Receptor CAR","volume":"73","author":"Kirby","year":"1999","journal-title":"J. Virol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1006\/mthe.2002.0613","article-title":"In Vivo Hepatic Adenoviral Gene Delivery Occurs Independently of the Coxsackievirus\u2013Adenovirus Receptor","volume":"5","author":"Smith","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"27926","DOI":"10.18632\/oncotarget.8545","article-title":"Pseudotyped \u03b1v\u03b26 integrin-targeted adenovirus vectors for ovarian cancer therapies","volume":"7","author":"Davies","year":"2016","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/sj.gt.3301515","article-title":"CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors","volume":"8","author":"Alemany","year":"2001","journal-title":"Gene Ther."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Seiradake, E., Henaff, D., Wodrich, H., Billet, O., Perreau, M., Hippert, C., Mennechet, F., Schoehn, G., Lortat-Jacob, H., and Dreja, H. (2009). The cell adhesion molecule \u201cCAR\u201d and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000277"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ymthe.2004.05.020","article-title":"Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats","volume":"10","author":"Nicol","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1469-1809.1985.tb01673.x","article-title":"A human cell-surface antigen defined by a monoclonal antibody and controlled by a gene on human chromosome 1","volume":"49","author":"Andrews","year":"1985","journal-title":"Ann. Hum. Genet."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.biocel.2013.09.016","article-title":"CD46: The \u2018multitasker\u2019 of complement proteins","volume":"45","author":"Yamamoto","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Persson, B.D., Schmitz, N.B., Santiago, C., Zocher, G., Larvie, M., Scheu, U., Casasnovas, J.M., and Stehle, T. (2010). Structure of the Extracellular Portion of CD46 Provides Insights into Its Interactions with Complement Proteins and Pathogens. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001122"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1099\/vir.0.83142-0","article-title":"Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor","volume":"88","author":"Fleischli","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nsmb1190","article-title":"Adenovirus type 11 binding alters the conformation of its receptor CD46","volume":"14","author":"Persson","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1073\/pnas.1017146108","article-title":"Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation","volume":"108","author":"Adams","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Hay, J., Carter, D., Lieber, A., and Astier, A.L. (2014). Recombinant Ad35 adenoviral proteins as potent modulators of human T cell activation. Immunology.","DOI":"10.1111\/imm.12391"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"eaan2507","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1038\/sj.onc.1204862","article-title":"The role of adenovirus E4orf4 protein in viral replication and cell killing","volume":"20","author":"Branton","year":"2001","journal-title":"Oncogene"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","article-title":"Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus","volume":"5","author":"Illingworth","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1128\/JVI.00928-12","article-title":"Adenovirus Serotype 26 Utilizes CD46 as a Primary Cellular Receptor and Only Transiently Activates T Lymphocytes following Vaccination of Rhesus Monkeys","volume":"86","author":"Li","year":"2012","journal-title":"J. Virol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/infdis\/jiu217","article-title":"First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002)","volume":"210","author":"Baden","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_144","unstructured":"(2017, September 23). Long-Term Safety Follow-Up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and\/or MVA-BN-Filo\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02661464?term=adenovirus&recrs=a&cond=ebola&rank=1."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys","volume":"86","author":"Teigler","year":"2012","journal-title":"J. Virol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.3390\/v7112923","article-title":"Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications","volume":"7","author":"Davies","year":"2015","journal-title":"Viruses"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.virol.2005.06.030","article-title":"Synthesis, cellular localization, and quantification of penton-dodecahedron in serotype 3 adenovirus-infected cells","volume":"340","author":"Fender","year":"2005","journal-title":"Virology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jmb.2005.11.048","article-title":"Structure of the dodecahedral penton particle from human adenovirus type 3","volume":"356","author":"Fuschiotti","year":"2006","journal-title":"J. Mol. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1128\/JVI.00514-11","article-title":"Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial Junctions","volume":"85","author":"Wang","year":"2011","journal-title":"J. Virol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Lu, Z.-Z., Wang, H., Zhang, Y., Cao, H., Li, Z., Fender, P., and Lieber, A. (2013). Penton-Dodecahedral Particles Trigger Opening of Intercellular Junctions and Facilitate Viral Spread during Adenovirus Serotype 3 Infection of Epithelial Cells. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003718"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1128\/JVI.07127-11","article-title":"Impact of Human Adenovirus Type 3 Dodecahedron on Host Cells and Its Potential Role in Viral Infection","volume":"86","author":"Fender","year":"2012","journal-title":"J. Virol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/pros.21070","article-title":"Chimeric Adenoviral Vectors Incorporating a Fiber of Human Adenovirus 3 Efficiently Mediate Gene Transfer into Prostate Cancer Cells","volume":"70","author":"Murakami","year":"2010","journal-title":"Prostate"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","article-title":"A phase I clinical trial of Ad5\/3-\u039424, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","volume":"130","author":"Kim","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_156","unstructured":"(2018, March 20). ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01598129."},{"key":"ref_157","unstructured":"(2018, March 20). A Phase 1\/2 Study to Investigate the Safety, Biologic and Anti-Tumor Activity of ONCOS-102 in Combination with Durvalumab in Subjects with Advanced Peritoneal Malignancies\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02963831."},{"key":"ref_158","unstructured":"(2018, March 20). A Randomised Phase II Open-Label Study with a Phase Ib Safety Lead-In Cohort of ONCOS-102, an Immune-Priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed\/Cisplatin in Patients with Unresectable Malignant Pleural Mesothelioma\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02879669."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/0008-5472.CAN-11-2009","article-title":"Epithelial Junction Opener JO-1 Improves Monoclonal Antibody Therapy of Cancer","volume":"71","author":"Beyer","year":"2011","journal-title":"Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-11-3213","article-title":"Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs","volume":"18","author":"Beyer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/mtm.2015.5","article-title":"Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin","volume":"2","author":"Richter","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/viro.2001.0967","article-title":"Structure of the fiber head of Ad3, a non-CAR-binding serotype of adenovirus","volume":"285","author":"Durmort","year":"2001","journal-title":"Virology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1128\/JVI.00205-12","article-title":"A New Human DSG2-Transgenic Mouse Model for Studying the Tropism and Pathology of Human Adenoviruses","volume":"86","author":"Wang","year":"2012","journal-title":"J. Virol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22816","article-title":"Upholding a role for EMT in breast cancer metastasis","volume":"547","author":"Ye","year":"2017","journal-title":"Nature"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.celrep.2016.02.034","article-title":"Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity","volume":"14","author":"Beerling","year":"2016","journal-title":"Cell Rep."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/1878-0261.12083","article-title":"EMT and MET: Necessary or permissive for metastasis?","volume":"11","author":"Jolly","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrmicro3346","article-title":"The sweet spot: Defining virus\u2013sialic acid interactions","volume":"12","author":"Reiss","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"8834","DOI":"10.1128\/JVI.76.17.8834-8841.2002","article-title":"Adenovirus Type 37 Uses Sialic Acid as a Cellular Receptor on Chang C Cells","volume":"76","author":"Arnberg","year":"2002","journal-title":"J. Virol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1128\/JVI.74.1.42-48.2000","article-title":"Adenovirus Type 37 Uses Sialic Acid as a Cellular Receptor","volume":"74","author":"Arnberg","year":"2000","journal-title":"J. Virol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Lenman, A., Liaci, A.M., Liu, Y., \u00c5rdahl, C., Rajan, A., Nilsson, E., Bradford, W., Kaeshammer, L., Jones, M.S., and Fr\u00e4ngsmyr, L. (2015). Human Adenovirus 52 Uses Sialic Acid-containing Glycoproteins and the Coxsackie and Adenovirus Receptor for Binding to Target Cells. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004657"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Lenman, A., Liaci, A.M., Liu, Y., Fr\u00e4ngsmyr, L., Frank, M., Blaum, B.S., Chai, W., Podgorski, I.I., Harrach, B., and Benk\u0151, M. (2018). Polysialic acid is a cellular receptor for human adenovirus 52. Proc. Natl. Acad. Sci. USA, 201716900.","DOI":"10.1073\/pnas.1716900115"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1152\/physrev.00033.2013","article-title":"Sialic Acids in the Brain: Gangliosides and Polysialic Acid in Nervous System Development, Stability, Disease, and Regeneration","volume":"94","author":"Schnaar","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/10409238.2014.976606","article-title":"Polysialic acid: Biosynthesis, novel functions and applications","volume":"49","author":"Colley","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrn2285","article-title":"Polysialic acid in the plasticity of the developing and adult vertebrate nervous system","volume":"9","author":"Rutishauser","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Galuska, C.E., L\u00fctteke, T., and Galuska, S.P. (2017). Is Polysialylated NCAM Not Only a Regulator during Brain Development But also during the Formation of Other Organs?. Biology, 6.","DOI":"10.3390\/biology6020027"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.aad0512","article-title":"Polysialylation controls dendritic cell trafficking by regulating chemokine recognition","volume":"351","author":"Kiermaier","year":"2016","journal-title":"Science"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/glycob\/cwi071","article-title":"Polysialic acid facilitates tumor invasion by glioma cells","volume":"15","author":"Suzuki","year":"2005","journal-title":"Glycobiology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00701-009-0324-3","article-title":"Polysialic acid overexpression in malignant astrocytomas","volume":"151","author":"Petridis","year":"2009","journal-title":"Acta Neurochir."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Amoureux, M.-C., Coulibaly, B., Chinot, O., Loundou, A., Metellus, P., Rougon, G., and Figarella-Branger, D. (2010). Polysialic Acid Neural Cell Adhesion Molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-91"},{"key":"ref_181","first-page":"6364","article-title":"Differential Spectrum of Expression of Neural Cell Adhesion Molecule Isoforms and L1 Adhesion Molecules on Human Neuroectodermal Tumors","volume":"50","author":"Durbec","year":"1990","journal-title":"Cancer Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/S0022-3468(98)90488-2","article-title":"Polysialylated neural cell adhesion molecule as a marker for differential diagnosis in pediatric tumors","volume":"33","author":"Schelp","year":"1998","journal-title":"J. Pediatr. Surg."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/00000478-199810000-00012","article-title":"Neural Cell Adhesion Molecules (ncam) and Ncam-psa Expression in Neuroendocrine Lung Tumors","volume":"22","author":"Lantuejoul","year":"1998","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_184","first-page":"3072","article-title":"Expression of Polysialic Acid and STX, a Human Polysialyltransferase, Is Correlated with Tumor Progression in Non-Small Cell Lung Cancer","volume":"60","author":"Tanaka","year":"2000","journal-title":"Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3390\/v7052592","article-title":"Interaction of Human Tumor Viruses with Host Cell Surface Receptors and Cell Entry","volume":"7","author":"Blumenthal","year":"2015","journal-title":"Viruses"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/S1462399409001367","article-title":"Proteoglycans in host\u2013pathogen interactions: Molecular mechanisms and therapeutic implications","volume":"12","author":"Bartlett","year":"2010","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Tuve, S., Wang, H., Jacobs, J.D., Yumul, R.C., Smith, D.F., and Lieber, A. (2008). Role of Cellular Heparan Sulfate Proteoglycans in Infection of Human Adenovirus Serotype 3 and 35. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000189"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/viro.1999.0171","article-title":"Heparan Sulfate Glycosaminoglycans Are Involved in Adenovirus Type 5 and 2-Host Cell Interactions","volume":"268","author":"Dechecchi","year":"2000","journal-title":"Virology"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1128\/JVI.75.18.8772-8780.2001","article-title":"Heparan Sulfate Glycosaminoglycans Are Receptors Sufficient To Mediate the Initial Binding of Adenovirus Types 2 and 5","volume":"75","author":"Dechecchi","year":"2001","journal-title":"J. Virol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"13369","DOI":"10.1016\/S0021-9258(18)80001-1","article-title":"Proteoglycans in cell regulation","volume":"264","author":"Ruoslahti","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/hum.2009.038","article-title":"Replacement of Adenovirus Type 5 Fiber Shaft Heparan Sulfate Proteoglycan-Binding Domain with RGD for Improved Tumor Infectivity and Targeting","volume":"20","author":"Gros","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","article-title":"Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes","volume":"108","author":"Parker","year":"2006","journal-title":"Blood"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/mt.2008.132","article-title":"Substitution of Hexon Hypervariable Region 5 of Adenovirus Serotype 5 Abrogates Blood Factor Binding and Limits Gene Transfer to Liver","volume":"16","author":"Vigant","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2009-12-260026","article-title":"Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors","volume":"116","author":"Alba","year":"2010","journal-title":"Blood"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/gt.2016.32","article-title":"The relevance of coagulation factor X protection of adenoviruses in human sera","volume":"23","author":"Duffy","year":"2016","journal-title":"Gene Ther."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Ma, J., Duffy, M.R., Deng, L., Dakin, R.S., Uil, T., Custers, J., Kelly, S.M., McVey, J.H., Nicklin, S.A., and Baker, A.H. (2015). Manipulating Adenovirus Hexon Hypervariable Loops Dictates Immune Neutralisation and Coagulation Factor X-dependent Cell Interaction In Vitro and In Vivo. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004673"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/gt.2011.87","article-title":"Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus)","volume":"19","author":"Alba","year":"2012","journal-title":"Gene Ther."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Bradshaw, A.C., Parker, A.L., Duffy, M.R., Coughlan, L., Rooijen, N. van, K\u00e4h\u00e4ri, V.-M., Nicklin, S.A., and Baker, A.H. (2010). Requirements for Receptor Engagement during Infection by Adenovirus Complexed with Blood Coagulation Factor X. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001142"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Corjon, S., Gonzalez, G., Henning, P., Grichine, A., Lindholm, L., Boulanger, P., Fender, P., and Hong, S.-S. (2011). Cell Entry and Trafficking of Human Adenovirus Bound to Blood Factor X Is Determined by the Fiber Serotype and Not Hexon:Heparan Sulfate Interaction. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018205"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/sj.gt.3302830","article-title":"A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-\u039424, for the treatment of advanced breast cancer","volume":"14","author":"Ranki","year":"2007","journal-title":"Gene Ther."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Capasso, C., Hirvinen, M., Garofalo, M., Romaniuk, D., Kuryk, L., Sarvela, T., Vitale, A., Antopolsky, M., Magarkar, A., and Viitala, T. (2015). Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology, 5.","DOI":"10.1080\/2162402X.2015.1105429"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1089\/hum.2005.16.1346","article-title":"Serotype Specificity of Adenovirus Purification Using Anion-Exchange Chromatography","volume":"16","author":"Konz","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins \u03b1v\u03b23 and \u03b1v\u03b25 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1099\/0022-1317-64-5-1091","article-title":"Ultrastructural and Immunofluorescence Studies of Early Events in Adenovirus-HeLa Cell Interactions","volume":"64","author":"Patterson","year":"1983","journal-title":"J. Gen. Virol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1128\/JVI.72.3.2055-2061.1998","article-title":"Adenovirus Endocytosis via \u03b1v Integrins Requires Phosphoinositide-3-OH Kinase","volume":"72","author":"Li","year":"1998","journal-title":"J. Virol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1128\/JVI.72.11.8806-8812.1998","article-title":"Adenovirus Endocytosis Requires Actin Cytoskeleton Reorganization Mediated by Rho Family GTPases","volume":"72","author":"Li","year":"1998","journal-title":"J. Virol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jconrel.2012.05.025","article-title":"Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses","volume":"164","author":"Bradshaw","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1128\/jvi.68.10.6811-6814.1994","article-title":"Multiple adenovirus serotypes use alpha v integrins for infection","volume":"68","author":"Mathias","year":"1994","journal-title":"J. Virol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1128\/JVI.75.11.5405-5409.2001","article-title":"Integrin \u03b1v\u03b21 Is an Adenovirus Coreceptor","volume":"75","author":"Li","year":"2001","journal-title":"J. Virol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/jgm.223","article-title":"Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be modulated by changes in beta1 integrin function","volume":"3","author":"Davison","year":"2001","journal-title":"J. Gene Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1128\/jvi.70.7.4502-4508.1996","article-title":"Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells","volume":"70","author":"Huang","year":"1996","journal-title":"J. Virol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1128\/jvi.71.8.6204-6207.1997","article-title":"Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2\/16","volume":"71","author":"Davison","year":"1997","journal-title":"J. Virol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"11491","DOI":"10.1128\/JVI.01214-09","article-title":"Cryo-Electron Microscopy Structure of an Adenovirus-Integrin Complex Indicates Conformational Changes in both Penton Base and Integrin","volume":"83","author":"Lindert","year":"2009","journal-title":"J. Virol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1002\/jgm.553","article-title":"Adenovirus endocytosis","volume":"6","author":"Meier","year":"2004","journal-title":"J. Gene Med."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1152\/physrev.1997.77.3.759","article-title":"Endocytosis","volume":"77","author":"Mukherjee","year":"1997","journal-title":"Physiol. Rev."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1128\/JVI.74.6.2731-2739.2000","article-title":"Regulation of Adenovirus Membrane Penetration by the Cytoplasmic Tail of Integrin \u03b25","volume":"74","author":"Wang","year":"2000","journal-title":"J. Virol."},{"key":"ref_218","unstructured":"Chiu, C.Y., Mathias, P., Nemerow, G.R., and Stewart, P.L. (2018, April 19). Structure of Adenovirus Complexed with Its Internalization Receptor, \u03b1v\u03b25 Integrin. Available online: http:\/\/jvi.asm.org."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/337709a0","article-title":"The three-dimensional structure of foot-and-mouth disease virus at 2.9 \u00c5 resolution","volume":"337","author":"Acharya","year":"1989","journal-title":"Nature"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.1128\/jvi.71.11.8357-8361.1997","article-title":"Arginine-glycine-aspartic acid-specific binding by foot-and-mouth disease viruses to the purified integrin alpha(v)beta3 in vitro","volume":"71","author":"Jackson","year":"1997","journal-title":"J. Virol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1743-422X-7-148","article-title":"Integrin \u03b1v\u03b25 is a primary receptor for adenovirus in CAR-negative cells","volume":"7","author":"Lyle","year":"2010","journal-title":"Virol. J."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1128\/JVI.77.13.7225-7235.2003","article-title":"Flexibility of the Adenovirus Fiber Is Required for Efficient Receptor Interaction","volume":"77","author":"Wu","year":"2003","journal-title":"J. Virol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"12322","DOI":"10.1128\/JVI.01608-12","article-title":"Conserved fiber-penton base interaction revealed by nearly atomic resolution cryo-electron microscopy of the structure of adenovirus provides insight into receptor interaction","volume":"86","author":"Cao","year":"2012","journal-title":"J. Virol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1128\/jvi.71.11.8798-8807.1997","article-title":"The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors","volume":"71","author":"Lieber","year":"1997","journal-title":"J. Virol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1128\/JVI.76.9.4580-4590.2002","article-title":"Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors","volume":"76","author":"Zaiss","year":"2002","journal-title":"J. Virol."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Paolo, N.C.D., Baldwin, L.K., Irons, E.E., Papayannopoulou, T., Tomlinson, S., and Shayakhmetov, D.M. (2014). IL-1\u03b1 and Complement Cooperate in Triggering Local Neutrophilic Inflammation in Response to Adenovirus and Eliminating Virus-Containing Cells. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004035"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e00670-17","DOI":"10.1128\/mBio.00670-17","article-title":"Key Role of the Scavenger Receptor MARCO in Mediating Adenovirus Infection and Subsequent Innate Responses of Macrophages","volume":"8","author":"Maler","year":"2017","journal-title":"mBio"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1128\/JVI.02702-13","article-title":"Adenovirus Detection by the cGAS\/STING\/TBK1 DNA Sensing Cascade","volume":"88","author":"Lam","year":"2014","journal-title":"J. Virol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.trecan.2016.01.002","article-title":"Adding STING to the Tale of Oncolytic Virotherapy","volume":"2","author":"Thorne","year":"2016","journal-title":"Trends Cancer"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"130.28","DOI":"10.4049\/jimmunol.198.Supp.130.28","article-title":"Defective STING signaling in ovarian cancer cells favor oncolytic virus action","volume":"198","author":"Xia","year":"2017","journal-title":"J. Immunol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41388-017-0120-0","article-title":"Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production","volume":"37","author":"Konno","year":"2018","journal-title":"Oncogene"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.gt.3302875","article-title":"Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector","volume":"14","author":"Myhre","year":"2007","journal-title":"Gene Ther."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus Serotype 5-Specific Neutralizing Antibodies Target Multiple Hexon Hypervariable Regions","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus Serotype 5 Neutralizing Antibodies Target both Hexon and Fiber following Vaccination and Natural Infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1110\/ps.8.11.2245","article-title":"Intrabody construction and expression III: Engineering hyperstable V(H) domains","volume":"8","author":"Wirtz","year":"1999","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jgm.285","article-title":"Genetic retargeting of adenovirus vectors: Functionality of targeting ligands and their influence on virus viability","volume":"4","author":"Magnusson","year":"2002","journal-title":"J. Gene Med."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"18133","DOI":"10.1038\/srep18133","article-title":"A novel single-chain antibody redirects adenovirus to IL13R\u03b12-expressing brain tumors","volume":"5","author":"Kim","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"10074","DOI":"10.1128\/JVI.02665-09","article-title":"Retargeting of Adenovirus Vectors through Genetic Fusion of a Single-Chain or Single-Domain Antibody to Capsid Protein IX","volume":"84","author":"Poulin","year":"2010","journal-title":"J. Virol."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Glasgow, J.N., Mikheeva, G., Krasnykh, V., and Curiel, D.T. (2009). A Strategy for Adenovirus Vector Targeting with a Secreted Single Chain Antibody. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0008355"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1006\/mthe.2001.0342","article-title":"Targeting of Adenovirus to Endothelial Cells by a Bispecific Single-Chain Diabody Directed against the Adenovirus Fiber Knob Domain and Human Endoglin (CD105)","volume":"3","author":"Nettelbeck","year":"2001","journal-title":"Mol. Ther."},{"key":"ref_241","first-page":"609","article-title":"Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain","volume":"62","author":"Kashentseva","year":"2002","journal-title":"Cancer Res."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody Molecules in Biotechnological and Medical Applications","volume":"35","author":"Frejd","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1089\/10430340260185067","article-title":"Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A","volume":"13","author":"Henning","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.cgt.7701027","article-title":"Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2\/neu","volume":"14","author":"Magnusson","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.01896-07","article-title":"Modification of Adenovirus Capsid with a Designed Protein Ligand Yields a Gene Vector Targeted to a Major Molecular Marker of Cancer","volume":"82","author":"Belousova","year":"2008","journal-title":"J. Virol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/hum.2011.016","article-title":"A Transductionally Retargeted Adenoviral Vector for Virotherapy of Her2\/neu-Expressing Prostate Cancer","volume":"23","author":"Magnusson","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"eaao1641","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy","volume":"10","author":"Roy","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"eaam7577","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrurol.2018.10","article-title":"Potentiating prostate cancer immunotherapy with oncolytic viruses","volume":"15","author":"Lee","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00262-017-2025-8","article-title":"Oncolytic immunotherapy: Unlocking the potential of viruses to help target cancer","volume":"66","author":"Hamid","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Guo, Z.S., Liu, Z., Kowalsky, S., Feist, M., Kalinski, P., Lu, B., Storkus, W.J., and Bartlett, D.L. (2017). Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00555"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/gt.2008.160","article-title":"Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber","volume":"16","author":"Myhre","year":"2009","journal-title":"Gene Ther."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"53414","DOI":"10.18632\/oncotarget.10800","article-title":"Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43","volume":"7","author":"Belousova","year":"2016","journal-title":"Oncotarget"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/gt.2011.162","article-title":"A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction","volume":"19","author":"Vrij","year":"2012","journal-title":"Gene Ther."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1128\/JVI.79.5.3206-3210.2005","article-title":"The Coiled-Coil Domain of the Adenovirus Type 5 Protein IX Is Dispensable for Capsid Incorporation and Thermostability","volume":"79","author":"Vellinga","year":"2005","journal-title":"J. Virol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ymthe.2004.01.012","article-title":"Use of adenovirus protein IX (pIX) to display large polypeptides on the virion\u2014Generation of fluorescent virus through the incorporation of pIX-GFP","volume":"9","author":"Meulenbroek","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ymthe.2004.03.006","article-title":"Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector","volume":"9","author":"Campos","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/JVI.78.7.3470-3479.2004","article-title":"Spacers Increase the Accessibility of Peptide Ligands Linked to the Carboxyl Terminus of Adenovirus Minor Capsid Protein IX","volume":"78","author":"Vellinga","year":"2004","journal-title":"J. Virol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0092-8674(93)90382-Z","article-title":"Stepwise dismantling of adenovirus 2 during entry into cells","volume":"75","author":"Greber","year":"1993","journal-title":"Cell"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.virol.2006.01.032","article-title":"Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting","volume":"349","author":"Campos","year":"2006","journal-title":"Virology"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Cysteine cathepsins: From structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nbt962","article-title":"High-affinity binders selected from designed ankyrin repeat protein libraries","volume":"22","author":"Binz","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jmb.2008.07.085","article-title":"Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display","volume":"382","author":"Steiner","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","article-title":"Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy","volume":"55","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"16111","DOI":"10.1038\/ncomms16111","article-title":"Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange","volume":"8","author":"Guillard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jmb.2010.10.040","article-title":"Her2-specific Multivalent Adapters Confer Designed Tropism to Adenovirus for Gene Targeting","volume":"405","author":"Dreier","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"E869","DOI":"10.1073\/pnas.1213653110","article-title":"Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters","volume":"110","author":"Dreier","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"11309","DOI":"10.1158\/0008-5472.CAN-07-0739","article-title":"An Oncolytic Adenovirus Redirected with a Tumor-Specific T-Cell Receptor","volume":"67","author":"Sebestyen","year":"2007","journal-title":"Cancer Res."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2012.05.011","article-title":"MAGE-A antigens as targets in tumour therapy","volume":"324","author":"Meek","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_271","doi-asserted-by":"crossref","unstructured":"Zajac, P., Schultz-Thater, E., Tornillo, L., Sadowski, C., Trella, E., Mengus, C., Iezzi, G., and Spagnoli, G.C. (2017). MAGE-A Antigens and Cancer Immunotherapy. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00018"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13238-016-0367-1","article-title":"T-cell receptor-engineered T cells for cancer treatment: Current status and future directions","volume":"9","author":"Ping","year":"2018","journal-title":"Protein Cell."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1128\/JVI.76.17.8621-8631.2002","article-title":"Modulation of Adenovirus Vector Tropism via Incorporation of Polypeptide Ligands into the Fiber Protein","volume":"76","author":"Belousova","year":"2002","journal-title":"J. Virol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/hum.2015.015","article-title":"Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies","volume":"26","author":"Legut","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1128\/JVI.75.16.7280-7289.2001","article-title":"Genetic Retargeting of Adenovirus: Novel Strategy Employing \u201cDeknobbing\u201d of the Fiber","volume":"75","author":"Magnusson","year":"2001","journal-title":"J. Virol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.gt.3303007","article-title":"Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob","volume":"14","author":"Miura","year":"2007","journal-title":"Gene Ther."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/gt.2009.1","article-title":"Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob","volume":"16","author":"Nishimoto","year":"2009","journal-title":"Gene Ther."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jgm.648","article-title":"Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma","volume":"7","author":"Drosten","year":"2005","journal-title":"J. Gene Med."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1128\/JVI.74.23.11359-11366.2000","article-title":"Recombinant Human Adenovirus: Targeting to the Human Transferrin Receptor Improves Gene Transfer to Brain Microcapillary Endothelium","volume":"74","author":"Xia","year":"2000","journal-title":"J. Virol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-398342-8.00002-1","article-title":"Adenovirus Strategies for Tissue-Specific Targeting","volume":"115","author":"Beatty","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2174\/138945009788680374","article-title":"Defining the Role of Integrin \u03b1v\u03b26 in Cancer","volume":"10","author":"Bandyopadhyay","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2009.12.006","article-title":"The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma","volume":"52","author":"Patsenker","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1038\/ncomms15408","article-title":"Rules of engagement between \u03b1v\u03b26 integrin and foot-and-mouth disease virus","volume":"8","author":"Kotecha","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/362566a0","article-title":"Structure of a major immunogenic site on foot-and-mouth disease virus","volume":"362","author":"Logan","year":"1993","journal-title":"Nature"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"9657","DOI":"10.1074\/jbc.M610461200","article-title":"Structure-Function Analysis of Arg-Gly-Asp Helix Motifs in \u03b1v\u03b26 Integrin Ligands","volume":"282","author":"DiCara","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1158\/0008-5472.CAN-07-1026","article-title":"Use of a Peptide Derived from Foot-and-Mouth Disease Virus for the Noninvasive Imaging of Human Cancer: Generation and Evaluation of 4-[18F]Fluorobenzoyl A20FMDV2 for In vivo Imaging of Integrin \u03b1v\u03b26 Expression with Positron Emission Tomography","volume":"67","author":"Hausner","year":"2007","journal-title":"Cancer Res."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1128\/JVI.00445-09","article-title":"In Vivo Retargeting of Adenovirus Type 5 to \u03b1v\u03b26 Integrin Results in Reduced Hepatotoxicity and Improved Tumor Uptake following Systemic Delivery","volume":"83","author":"Coughlan","year":"2009","journal-title":"J. Virol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/hum.2014.016","article-title":"Retargeting Adenovirus Serotype 48 Fiber Knob Domain by Peptide Incorporation","volume":"25","author":"Coughlan","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_289","doi-asserted-by":"crossref","unstructured":"Sela-Culang, I., Kunik, V., and Ofran, Y. (2013). The Structural Basis of Antibody-Antigen Recognition. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00302"},{"key":"ref_290","first-page":"153","article-title":"DARPins: A true alternative to antibodies","volume":"10","author":"Stumpp","year":"2007","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nature19946","article-title":"The coming of age of de novo protein design","volume":"537","author":"Huang","year":"2016","journal-title":"Nature"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/sj.mt.6300206","article-title":"The Influence of Blood on In Vivo Adenovirus Bio-distribution and Transduction","volume":"15","author":"Baker","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","article-title":"Restricted replication of human adenovirus type 5 in mouse cell lines","volume":"14","author":"Blair","year":"1989","journal-title":"Virus Res."},{"key":"ref_294","first-page":"169","article-title":"Use of the Syrian hamster as an animal model for oncolytic aladenovirus vectors","volume":"130","author":"Thomas","year":"2007","journal-title":"Methods Mol. Med."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1128\/jvi.71.8.6144-6154.1997","article-title":"Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding","volume":"71","author":"Hsu","year":"1997","journal-title":"J. Virol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1128\/MCB.23.7.2614-2622.2003","article-title":"Disruption of Mouse CD46 Causes an Accelerated Spontaneous Acrosome Reaction in Sperm","volume":"23","author":"Inoue","year":"2003","journal-title":"Mol. Cell. Biol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/6\/201\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:08:46Z","timestamp":1760195326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/6\/201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":296,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["cancers10060201"],"URL":"https:\/\/doi.org\/10.3390\/cancers10060201","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201805.0273.v1","asserted-by":"object"},{"id-type":"doi","id":"10.20944\/preprints201805.0273.v2","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]}}}